Bipolar is the fifth cause of disability among people aged between 15-44 years globally. The rate of complete suicide among people with bipolar disorder has been predicted to be sixty times more than for the unaffected population. On the other hand, the societal cost of bipolar in the United States of America is estimated to be $ 45 billion annually. The quality of life for a bipolar disorder patient is therefore characterized by occupational absenteeism and disability, interrelation instability, frequent hospitalization, reduced income, and premature death.
According to Basco, Ladd, Myers, and Tyler, bipolar disorder is characterized by interpersonal crisis, stressful life events, and insufficient stress management skills. At some level, pharmacological treatment is vital in managing the bipolar disorder. As observed by Miklolowitz and Otto pharmacological treatment cannot provide complete treatment to the bipolar disorder. Medication lacks the capacity of reinstating and maintaining the physical well-being of the patient while improving the patient quality of life. According to Miklolowitz and Otto (2006), the combination of medication and psychotherapy improves tremendously the long-standing production capacity of a patient. In this regard, sufficient incorporation of pharmacotherapy and psychotherapy improve significantly the performance and the quality of life of the patient and the entire family.
The core purpose of treating and managing bipolar disorder is to improve the production capability of the patient.